Details

Autor(en) / Beteiligte

• Kaplan, Lawrence D
• Straus, David J
• Testa, Marcia A
• Von Roenn, Jamie
• Dezube, Bruce J
• Cooley, Timothy P
• Herndier, Brian
• Northfelt, Donald W
• Huang, Jenny
• Tulpule, Anil
• Levine, Alexandra M

Titel

Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus Infection

Ist Teil von

• The New England journal of medicine, 1997-06, Vol.336 (23), p.1641-1648

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

1997

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The human immunodeficiency virus (HIV) increases the risk of aggressive B-cell lymphoma, 1 , 2 which often presents at an advanced stage and frequently involves extranodal sites, such as the central nervous system and bone marrow. 3 – 7 In HIV-infected patients, the rate of complete response to the treatment of lymphoma with combination chemotherapy is approximately 50 percent, and the median survival is only five to six months. 4 – 6 , 8 Factors that favor longer survival include a higher number of CD4+ lymphocytes, 4 , 9 the absence of a prior diagnosis indicating progression to the acquired immunodeficiency syndrome (AIDS), 4 , 9 a Karnofsky performance score of . . .